Clinical Trials Browser

Interventional × radium Ra 223 dichloride × 90 days × Clear all

NCT04071236 2026-03-19

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04090398 2026-03-19

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04071223 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04109729 2026-03-02

Rad2Nivo

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Phase 3 Completed

921 enrolled 43 charts

Hormone Refractory Prostate Cancer

NCT03317392 2026-02-19

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05133440 2026-01-21

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Phase 2 Active not recruiting

Prostatic Neoplasms